Article Text

Download PDFPDF
International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers
  1. Jennifer J. Mueller, MD*,
  2. Henrik Lajer, MD,
  3. Berit Jul Mosgaard, MD,
  4. Slim Bach Hamba, MD,
  5. Philippe Morice, MD§,
  6. Sebastien Gouy, MD§,
  7. Yaser Hussein, MD*,
  8. Robert A. Soslow, MD,
  9. Brooke A. Schlappe, MD*,
  10. Qin C. Zhou, MS,
  11. Alexia Iasonos, PhD,
  12. Claus Høgdall, MD,
  13. Alexandra Leary, MD,
  14. Roisin E. O’Cearbhaill, MD# and
  15. Nadeem R. Abu-Rustum, MD*
  1. * Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY;
  2. Department of Gynecology, Copenhagen University Hospital Rigshospitalet, Denmark; Departments of
  3. Medicine and INSERM U981 and
  4. § Surgery and INSERM U981, Gustave Roussy Cancer Campus, France; Departments of
  5. Pathology and
  6. Epidemiology and Biostatistics, and
  7. # Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  1. Address correspondence and reprint requests to Jennifer J. Mueller, MD, Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065. E-mail: muellerj{at}


Objective We sought to describe a large, international cohort of patients diagnosed with primary mucinous ovarian carcinoma (PMOC) across 3 tertiary medical centers to evaluate differences in patient characteristics, surgical/adjuvant treatment strategies, and oncologic outcomes.

Methods This was a retrospective review spanning 1976–2014. All tumors were centrally reviewed by an expert gynecologic pathologist. Each center used a combination of clinical and histologic criteria to confirm a PMOC diagnosis. Data were abstracted from medical records, and a deidentified dataset was compiled and processed at a single institution. Appropriate statistical tests were performed.

Results Two hundred twenty-two patients with PMOC were identified; all had undergone primary surgery. Disease stage distribution was as follows: stage I, 163 patients (74%); stage II, 8 (4%); stage III, 40 (18%); and stage IV, 10 (5%). Ninety-nine (45%) of 219 patients underwent lymphadenectomy; 41 (19%) of 215 underwent fertility-preserving surgery. Of the 145 patients (65%) with available treatment data, 68 (47%) had received chemotherapy—55 (81%) a gynecologic regimen and 13 (19%) a gastrointestinal regimen. The 5-year progression-free survival (PFS) rates were 80% (95% confidence interval [CI], 73%–85%) for patients with stage I to II disease and 17% (95% CI, 8%–29%) for those with stage III to IV disease. The 5-year PFS rate was 73% (95% CI, 50%–86%) for patients who underwent fertility-preserving surgery.

Conclusions Most patients (74%) presented with stage I disease. Nearly 50% were treated with adjuvant chemotherapy using various regimens across institutions. The PFS outcomes were favorable for those with early-stage disease and lower but acceptable for those who underwent fertility preservation.

  • Ovarian cancer
  • Primary mucinous ovarian cancer
  • Fertility preservation
  • Survival

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.